Skip to main content
. 2012 Dec 3;123(1):224–235. doi: 10.1172/JCI64516

Figure 3. GSK3β regulates BACE1 promoter activation.

Figure 3

(A) Schematic of the 3.3-kb (pB1-A) and 300-bp (pB1-B) human BACE1 promoter/luciferase construct. (B) The 3.5-kb human BACE1 promoter was transfected into N2a cells and treated with 5 μM ARA. GSK3 inhibition with ARA treatment resulted in a significant decrease in luciferase activity. (C) N2a cells were co-transfected with either promoter constructs and S9A-GSK3β or a vector control. S9A-GSK3β significantly increased the luciferase activity of the 3.3-kb BACE1 promoter construct but did not have any effect on the 300-bp promoter construct. (D) pB1-A or pB1-B constructs were transfected into Gsk3b-KO MEFs. pB1-A had significantly reduced promoter activity. All promoter data shown represent an average of at least 4 independent experiments, with each condition performed in triplicate. Values are expressed as mean ± SEM. n = 4; *P < 0.05, **P < 0.01, ***P < 0.005, Student’s t test.